Amoy Diagnostics 過去の業績

過去基準チェック /56

Amoy Diagnosticsは、平均年間15.2%の収益成長を遂げていますが、 Biotechs業界の収益は、年間成長しています。収益は、平均年間5.9% 13.2%収益成長率で成長しています。 Amoy Diagnosticsの自己資本利益率は17.4%であり、純利益率は26.6%です。

主要情報

15.2%

収益成長率

15.1%

EPS成長率

Biotechs 業界の成長	11.3%
収益成長率	13.2%
株主資本利益率	17.4%
ネット・マージン	26.6%
前回の決算情報	30 Sep 2024

Recent updates

収支内訳

Amoy Diagnostics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

XSEC:300685 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	1,184	315	426	217
30 Jun 24	1,128	279	424	218
31 Mar 24	1,082	268	402	215
31 Dec 23	1,044	261	390	203
30 Sep 23	951	213	383	204
30 Jun 23	908	301	378	189
31 Mar 23	831	267	364	173
01 Jan 23	842	264	367	175
30 Sep 22	871	287	395	168
30 Jun 22	911	218	390	166
31 Mar 22	949	250	388	162
01 Jan 22	917	240	374	156
30 Sep 21	890	231	373	138
30 Jun 21	844	211	364	130
31 Mar 21	811	198	356	127
31 Dec 20	728	180	339	115
30 Sep 20	650	153	308	115
30 Jun 20	595	138	292	106
31 Mar 20	550	129	284	96
31 Dec 19	578	135	294	94
30 Sep 19	541	140	265	87
30 Jun 19	502	135	241	86
31 Mar 19	469	134	215	85
31 Dec 18	439	127	201	78
30 Sep 18	398	122	186	69
30 Jun 18	384	120	156	84
31 Mar 18	357	103	161	64
31 Dec 17	330	94	157	51
30 Sep 17	315	82	163	39
30 Jun 17	288	78	193	0
31 Mar 17	258	67	180	0
31 Dec 16	253	67	181	0
30 Jun 16	220	42	168	0
31 Mar 16	198	32	157	0
31 Dec 15	177	21	147	0
31 Dec 14	107	19	82	0
31 Dec 13	74	22	52	0

質の高い収益: 300685は高品質の収益を持っています。

利益率の向上: 300685の現在の純利益率 (26.6%)は、昨年(22.4%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 300685の収益は過去 5 年間で年間15.2%増加しました。

成長の加速: 300685の過去 1 年間の収益成長率 ( 47.7% ) は、5 年間の平均 ( 年間15.2%を上回っています。

収益対業界: 300685の過去 1 年間の収益成長率 ( 47.7% ) はBiotechs業界0.08%を上回りました。

株主資本利益率

高いROE: 300685の自己資本利益率 ( 17.4% ) は低いとみなされます。

Amoy Diagnostics 過去の業績

過去 基準チェック /56

主要情報

最近の業績更新

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.12 in 3Q 2023)

Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2023)

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Full year 2023 earnings released: EPS: CN¥0.66 (vs CN¥0.67 in FY 2022)

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.12 in 3Q 2023)

Investor sentiment improves as stock rises 35%

Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024

Now 20% undervalued

Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 2Q 2023)

Now 20% undervalued after recent price drop

Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Dividend increased to CN¥0.15

Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024

Full year 2023 earnings released: EPS: CN¥0.66 (vs CN¥0.67 in FY 2022)

Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024

Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024.

Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Now 24% overvalued

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index

New minor risk - Profit margin trend

Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.087 in 2Q 2022)

Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.61 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.087 (vs CN¥0.17 in 2Q 2021)

Investor sentiment improved over the past week

Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022

Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022

Amoy Diagnostics Co., Ltd. Approves Dividend for 2021

High number of new directors

Amoy Diagnostics Co., Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings released: EPS: CN¥1.09 (vs CN¥0.82 in FY 2020)

Now 22% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares.

Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan

Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel

Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019)

New 90-day low: CN¥67.96

Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021

New 90-day high: CN¥92.11

New 90-day high: CN¥87.26

New 90-day low: CN¥71.91

New 90-day low: CN¥72.29

Third quarter earnings released

New 90-day high - CN¥88.26

New 90-day high - CN¥79.53

Amoy Diagnostics Co., Ltd. to Report First Half, 2020 Results on Jul 28, 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /56